全文获取类型
收费全文 | 1392930篇 |
免费 | 99586篇 |
国内免费 | 2997篇 |
专业分类
耳鼻咽喉 | 20103篇 |
儿科学 | 41924篇 |
妇产科学 | 40115篇 |
基础医学 | 194666篇 |
口腔科学 | 41091篇 |
临床医学 | 120784篇 |
内科学 | 272731篇 |
皮肤病学 | 30836篇 |
神经病学 | 111501篇 |
特种医学 | 55527篇 |
外国民族医学 | 435篇 |
外科学 | 214776篇 |
综合类 | 32207篇 |
现状与发展 | 6篇 |
一般理论 | 492篇 |
预防医学 | 99666篇 |
眼科学 | 32372篇 |
药学 | 104376篇 |
4篇 | |
中国医学 | 3074篇 |
肿瘤学 | 78827篇 |
出版年
2018年 | 12877篇 |
2016年 | 11488篇 |
2015年 | 12964篇 |
2014年 | 18176篇 |
2013年 | 27439篇 |
2012年 | 36183篇 |
2011年 | 38181篇 |
2010年 | 22540篇 |
2009年 | 21918篇 |
2008年 | 36588篇 |
2007年 | 39889篇 |
2006年 | 40343篇 |
2005年 | 39001篇 |
2004年 | 37948篇 |
2003年 | 36731篇 |
2002年 | 36237篇 |
2001年 | 65020篇 |
2000年 | 66627篇 |
1999年 | 56749篇 |
1998年 | 15383篇 |
1997年 | 14040篇 |
1996年 | 13448篇 |
1995年 | 12774篇 |
1994年 | 11953篇 |
1992年 | 43814篇 |
1991年 | 42209篇 |
1990年 | 41427篇 |
1989年 | 40398篇 |
1988年 | 37770篇 |
1987年 | 37211篇 |
1986年 | 35686篇 |
1985年 | 33862篇 |
1984年 | 25470篇 |
1983年 | 21589篇 |
1982年 | 13033篇 |
1981年 | 11894篇 |
1979年 | 24389篇 |
1978年 | 17458篇 |
1977年 | 15138篇 |
1976年 | 13699篇 |
1975年 | 15525篇 |
1974年 | 18418篇 |
1973年 | 17863篇 |
1972年 | 17096篇 |
1971年 | 15991篇 |
1970年 | 15162篇 |
1969年 | 14607篇 |
1968年 | 13672篇 |
1967年 | 12199篇 |
1966年 | 11413篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
To determine if impaired energy metabolism might contribute to some aspects of Alzheimer disease (AD), including the vulnerability of the CA1 region of the hippocampal formation and the altered cytoskeleton evident in neurofibrillary tangles, we examined the effects of metabolic poisons on neuronal damage and cytoskeletal disruption in the hippocampal formation. Intrahippocampal injection of 3-nitropropionic acid (3-NP) and malonic acid resulted in neuronal death, particularly in CA1. Cytoskeletal disruption included loss of dendritic MAP2, but sparing of axonal τ. MK-801 (a noncompetitive NMDA receptor antagonist) did not atenuate the lesions produced by intrahippocampal injection of malonate. MK-801, however, was effective against intrastriatal malonate. Acute systemic 3-NP resulted in neuronal damage and cytoskeletal disruption in the CA1 region of the hippocampal formation, including an extensive loss of MAP2 immuno-reactivity, but sparing of τ. The neuronal loss in CA1 was delayed as compared to striatum. Chronic intraventricular infusion of 3-NP produced a different pattern of neuronal damage. Loss of τ-1 immuno-reactivity was observed in CA3 and CA1 s. oriens, whereas MAP2 immunostaining was preserved. These results demonstrate that chronic and acute administration of metabolic inhibitors produce distinct patterns of neuronal damage and cytoskeletal disruption. The results further suggest a differential involvement of the NMDA receptor in malonate-induced neuronal damage in striatum as compared to the hippocampus. The pattern of neuronal damage and cytoskeletal disruption observed following acute metabolic impairment resembled some aspects of neurofibrillary pathology in AD, but did not result in τ hyperphosphorylation. 相似文献
43.
Effects of poor glucose handling on arterial stiffness and left ventricular mass in normal children.
AIM: Cardiovascular risk factors can be present in children and young adults. We previously found abnormal microvascular function in children who had glucose intolerance and insulin resistance. The aim of the present study was to investigate whether they also have abnormalities in left ventricular mass (LVM) and arterial stiffness. METHODS: We measured heart dimensions and LVM using echocardiography, and arterial stiffness using pulse wave analysis in 23 children with good glucose handling (postfeeding glucose: 3.9 to 5 mmol/L) and 21 with poor glucose handling (7.7 to 11.4 mmol/L). RESULTS: The time to pulse reflection was slightly shorter in the poorer glucose handlers (mean+/-SD: 143+/-10 vs 153+/-20 ms, P=0.04), suggestive of increased arterial stiffness. Also in this group, there were significant relationships between intraventricular septal thickness, blood pressure and body mass index, but not in the normal glucose handlers. CONCLUSIONS: We have found that normal children who are in the lowest quintile of glucose tolerance in comparison with their peers are exhibiting the first signs of arterial stiffening. In addition, we have seen the beginnings of a relationship between blood pressure, body mass index and left ventricular enlargement in this group. While these changes may not yet be clinically significant, their emergence might be further evidence of early predisposition to cardiovascular disease. 相似文献
44.
45.
Setting goals to maintain hope. 总被引:3,自引:0,他引:3
46.
47.
48.
Toshio Kushiro Hiroshige Itakura Yoshihisa Abo Hiromi Gotou Shinji Terao Deborah L Keefe 《Hypertension research》2006,29(12):997-1005
Aliskiren is a novel orally active renin inhibitor for the treatment of hypertension. This study evaluated the antihypertensive efficacy, safety and tolerability of aliskiren in Japanese patients with hypertension. Forty hundred and fifty-five Japanese men and women with a mean sitting diastolic blood pressure of 95-110 mmHg were randomized to receive once-daily double-blind treatment for 8 weeks with aliskiren 75, 150 or 300 mg or placebo. Aliskiren produced significant, dose-dependent reductions in mean sitting diastolic blood pressure (p<0.0005 vs. placebo for each dose) and mean sitting systolic blood pressure (p<0.001 vs. placebo for each dose). The placebo-corrected reductions in mean sitting systolic/diastolic blood pressure were 5.7/4.0, 5.9/4.5 and 11.2/7.5 mmHg in the aliskiren 75, 150 and 300 mg groups, respectively. After 8 weeks' treatment, 27.8%, 47.8%, 48.2% and 63.7% of patients in the placebo and aliskiren 75, 150 and 300 mg groups, respectively, achieved a successful treatment response (diastolic blood pressure <90 mmHg and/or reduced by > or =10 mmHg from baseline; p<0.005 vs. placebo for each dose). Aliskiren treatment was well tolerated, with the incidence of adverse events reported in the active treatment groups (53-55%) being similar to that in the placebo group (50%). This study, which is the first to assess the antihypertensive efficacy and safety of aliskiren in Japanese patients with hypertension, demonstrates that the once-daily oral renin inhibitor aliskiren provides significant, dose-dependent reductions in blood pressure with placebo-like tolerability. 相似文献
49.
50.